Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $44.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective increased by Piper Sandler from $42.00 to $44.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other analysts also recently issued research reports about the company. UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Truist Financial lifted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Barclays upped their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Teva Pharmaceutical Industries Trading Up 2.1%

NYSE:TEVA opened at $35.45 on Tuesday. Teva Pharmaceutical Industries has a 12 month low of $14.99 and a 12 month high of $37.35. The firm has a fifty day simple moving average of $33.22 and a 200-day simple moving average of $32.72. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $40.76 billion, a P/E ratio of 59.09, a PEG ratio of 3.67 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.59%. The firm had revenue of $4.14 billion for the quarter. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the transaction, the chief accounting officer owned 20,016 shares in the company, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. The trade was a 47.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 300,493 shares of company stock worth $10,537,510. Insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $25,000. Cornerstone Planning Group LLC grew its position in Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares during the period. Allworth Financial LP increased its holdings in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC increased its holdings in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported second-quarter revenue of approximately $4.14 billion, ahead of consensus estimates of $4.02 billion. Innovative medicines grew 43% year over year in local-currency terms, helping offset weaker generics sales. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: Management raised its 2026 revenue outlook to $16.5 billion-$16.9 billion and increased projections for its three key innovative brands, signaling confidence in the company’s branded-drug growth strategy. Teva Outlines Higher 2026 Revenue Outlook
• Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million, supporting optimism about its long-acting injectable portfolio. UZEDY Record Q2 Net Sales
• Positive Sentiment: Piper Sandler reportedly forecast substantial potential appreciation for TEVA, adding to bullish sentiment following the results. Piper Sandler Forecasts Strong Price Appreciation
• Neutral Sentiment: Options activity was unusually elevated: traders bought about 23,688 calls on Wednesday, followed by roughly 27,659 puts on Thursday. The activity indicates heightened speculation but does not establish a clear directional signal. Unusually Large Options Trading
• Negative Sentiment: Second-quarter EPS of $0.02 missed the $0.08 consensus estimate, while acquisition-related costs and impairment charges contributed to a reported net loss of $576 million. Full-year EPS guidance of $1.91-$2.11 also remains below the $2.17 consensus estimate. Teva Q2 Earnings Lag Estimates

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.